Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

The FDA has approved daratumumab and hyaluronidase (DARA SC; Darzalex Faspro, Janssen Biotech) for adults with high-risk ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

For the first time in more than a decade, a new frontline treatment for an incurable blood cancer is being added to the ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients ...